Clinical efficacy and tolerance of oral low-dose continuous estrogen-progestin therapy (Activelle)

Edyta Wlaźlak; Grzegorz Surkont; Jacek Suzin

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2002
vol. 1

Send email

Copy url:

abstract:

Clinical efficacy and tolerance of oral low-dose continuous estrogen-progestin therapy (Activelle)

Edyta Wlaźlak

,

Grzegorz Surkont

,

Jacek Suzin

(Prz Menopauz 2002; 4: 35–38)

Online publish date: 2004/03/03

View full text Get citation

New therapeutical option for hrt – oral low-dose continuous estrogen-progestin therapy with the use of 1 mg estradiol and 0.5 mg norethisterone acetate was evaluated in the article. We find Activelle (Novo Nordisk) effective in the treatment of menopausal symptoms. This drug is well tolerated by postmenopausal women. The frequency of side effects is low. The most common is spotting/bleeding: 22.6% patients in the first month of hrt, 6.9% treated women after 6 months.

keywords:

Clinical efficacy and tolerance of oral low-dose continuous estrogen-progestin therapy (Activelle)

Edyta Wlaźlak , Grzegorz Surkont , Jacek Suzin

menopause, low-dose hrt

Edyta Wlaźlak

,

Grzegorz Surkont

,

Jacek Suzin